Research article | Open | Published:
The neuroprotective effect of post ischemic brief mild hypothermic treatment correlates with apoptosis, but not with gliosis in endothelin-1 treated rats
BMC Neurosciencevolume 13, Article number: 105 (2012)
Stroke remains one of the most common diseases with a serious impact on quality of life but few effective treatments exist. Mild hypothermia (33°C) is a promising neuroprotective therapy in stroke management. This study investigated whether a delayed short mild hypothermic treatment is still beneficial as neuroprotective strategy in the endothelin-1 (Et-1) rat model for a transient focal cerebral ischemia. Two hours of mild hypothermia (33°C) was induced 20, 60 or 120 minutes after Et-1 infusion. During the experiment the cerebral blood flow (CBF) was measured via Laser Doppler Flowmetry in the striatum, which represents the core of the infarct. Functional outcome and infarct volume were assessed 24 hours after the insult. In this sub-acute phase following stroke induction, the effects of the hypothermic treatment on apoptosis, phagocytosis and astrogliosis were assessed as well. Apoptosis was determined using caspase-3 immunohistochemistry, phagocytic cells were visualized by CD-68 expression and astrogliosis was studied by glial fibrillary acidic protein (GFAP) staining.
Cooling could be postponed up to 1 hour after the onset of the insult without losing its positive effects on neurological deficit and infarct volume. These results correlated with the caspase-3 staining. In contrast, the increased CD-68 expression post-stroke was reduced in the core of the insult with all treatment protocols. Hypothermia also reduced the increased levels of GFAP staining, even when it was delayed up to 2 hours after the insult. The study confirmed that the induction of the hypothermia treatment in the Et-1 model does not affect the CBF.
These data indicate that in the Et-1 rat model, a short mild hypothermic treatment delayed for 1 hour is still neuroprotective and correlates with apoptosis. At the same time, hypothermia also establishes a lasting inhibitory effect on the activation of astrogliosis.
Stroke is an important cause of death worldwide and recombinant tissue plasminogen activator remains the only approved treatment . However, the limited time window for its administration restricts its usefulness. Given the numerous pathways via which ischemia causes cell death, the capacity to inhibit multiple mechanisms simultaneously may provide additive clinical benefits for stroke patients [2, 3]. Therapeutic hypothermia has given positive effects in cardiac arrest and newborns with hypoxic-ischemic encephalopathy [2, 4, 5]. A number of small clinical trials have been performed in stroke patients subjected to hypothermia, such as the “Cooling for Acute Ischemic Brain Damage” study and the “Intravascular Cooling in the Treatment of Stroke–Longer tPA window” study [6, 7]. Both studies confirmed that cooling patients is feasible. However, no reduced mortality could be shown. Several studies in animals have shown that although brief durations of pre-insult hypothermia may be sufficient to protect against cerebral ischemia, longer durations are necessary when started in the post-ischemic period [8, 9]. However, the risk of complications increases with treatment duration, such as pneumonia hypovolemia, arrhythmias, hyperglycemia, bradycardia, thrombocytopenia, hypertension, hypotension, increased intracranial pressure, electrolyte abnormalities like hypokalemia and metabolic acidosis [7, 10–13]. Evidently, hypothermic treatments should be as short as possible. Indeed, with respect to the well-known time is brain concept, it is crucial to induce a beneficial effect as early as possible and to start a treatment with as little side-effects as possible. Therefore, it is essential that the ideal therapeutic time window of a short hypothermic treatment should be determined in order to avoid long cooling times and this without further impairment of the neurological outcome. Many have proven that 2 hours of mild hypothermia is neuroprotective and can reduce infarct volume after MCAO [3, 9, 14–26]. Experimental research remains vital to establish the ideal length of the therapeutic hypothermic treatment and this without increasing hypothermia related complications [13, 27–29]. As there is no ideal experimental stroke model, it is essential that such parameters are investigated in various animal models mimicking different types of stroke. In contrast to other Middle Cerebral Artery Occlusion (MCAO) models, the endothelin-1 (Et-1) model allows the study of the effects of cooling during a slow reperfusion phase [20, 30–33]. Although longer cooling times (minimum 12 hours) in rat models seem more protective [34, 35] than short ones (a few hours), investigation into efficient shorter cooling strategies remains relevant as long hypothermic treatments may increase the risk of complications and/or have an influence on different organ systems [13, 36]. We previously showed that a 2 hours mild hypothermic treatment, started 20 minutes after the onset of the insult can reduce infarct volume up to 1 week after an Et-1 induced stroke. This beneficial effect was related to effects on apoptosis, oxidative stress and the inflammatory response [20, 21, 37].
Here, we investigated how long a short mild hypothermic treatment can be postponed without reducing its neuroprotective effect after a transient cerebral ischemia induced by Et-1. The study investigated first whether a hypothermia treatment exerts an effect on the cerebral blood flow (CBF). Secondly, since apoptosis and neuroinflammation are important pathways in cell death in the subacute phase after ischemia, activated caspase-3, phagocytosis (CD-68 expression) and astrogliosis (glial fibrillary acidic protein (GFAP) staining) were investigated. The effects were assessed after 24 hours since the most pronounced effects of this hypothermic treatment on apoptosis, phagocytosis and astrogliosis occur at that time point.
The experiments were performed according to the National Guidelines on Animal Experimentation and approved by the Ethical Committee for Animal Experimentation of the Faculty of Medicine and Pharmacy of the Vrije Universiteit Brussel.
Experimental and surgical protocols
Experiments were carried out in male Wistar rats weighing 270-300 g (Charles River Laboratories, IFFA-CREDO, Germany). A day before the induction of the insult, 2 intracerebral guide cannulas were stereotactically implanted under anaesthesia (ketamine/diazepam 75:4 mg/kg i.p.) [21, 37]. An Et-1 administration probe was positioned close to the middle cerebral artery (MCA) (relative to bregma: AP +0.9 mm; L +5.0 mm; V +2.8 mm) and a thermocouple probe was positioned in the contralateral prefrontal cortex (AP +3.2 mm; L −3.0 mm; V +2.3 mm) . As post-operative analgesia, the rats received 4 mg/kg ketoprofen (i.p.). After surgery, the rats were allowed to recover overnight. The next day the animals were anaesthetized with 4% sevoflurane (Sevorane®, Abbott, Kent, England) and oxygen insufflated into a transparent chamber. During the experiments, anaesthesia was maintained by 2% sevoflurane with oxygen at 0.8 ml/min via a facemask. The guides were replaced by a microdialysis probe without a membrane (CMA, 3 mm probe with removed membrane, Stockholm, Sweden) and a thermocouple probe (HYP-O-SLE, Omega Corporation, Stamford, USA) to infuse Et-1 and measure the brain temperature respectively. Heart rate, oxygen saturation and temperature were continuously monitored during the experimental procedure. Transient focal cerebral ischemia was induced by infusion of Et-1 (Sigma, St-Louis, MO, USA) dissolved in Ringer’s solution (500pmol/6 μl) through the probe near the MCA at a flow rate of 1 μl/min. In sham experiments, only Ringer’s solution was injected. By infusing Et-1 adjacent to the MCA, a reproducible insult can be obtained in which the core is represented by the striatum and the penumbra by the surrounding cortex [21, 37]. In normothermic rats, the brain temperature was maintained at 37.0 ± 0.5°C throughout the experiment using a heating pad and an infrared lamp. In the hypothermic group, the temperature was reduced to 33.0 ± 0.5°C during 2 hours starting with a delay of 20, 60 or 120 minutes after the ischemic insult. Cooling the animal to the target temperature was achieved by spraying alcohol onto the animal and cooling it with a fan. With this method the brain temperature can be decreased from 37.0 to 33.0°C within 10 minutes. A heating pad and an infrared lamp were used to re-warm the animal from 33.0 to 37.0°C in 30 minutes. Finally, all rats were kept at 37°C for another 30 minutes before the anaesthesia was stopped. Laser-doppler flowmetry experiments were preformed in the striatum of some animals to investigated the influence of cooling on the MCA occlusion caused by Et-1. Twenty-four hours after the induction of the ischemic insult, the effects on neurological outcome (neurological deficit score), infarct volume, apoptosis (active caspase-3 staining) and activation of microglia and astrocytes (CD-68 and GFAP expression, respectively) were evaluated.
In total, 44 rats were randomized into 6 experimental groups (Figure 1). Sham rats (S group) were injected with the vehicle of Et-1 and the brain temperature was kept constant at 37.0 ± 0.5°C (n = 7) while in sham rats that received the hypothermic treatment (S + H group, n = 4), brain temperature was reduced to 33.0 ± 0.5°C. Normothermic rats (N group) were injected with Et-1. These animals were not cooled and their brain temperature was maintained at 37.0 ± 0.5°C (n = 12). Hypothermic rats were infused with Et-1 and to determine how long the hypothermic treatment protocol could be delayed, cooling was started 20 (H20 group, n = 7), 60 (H60 group, n = 7) or 120 minutes (H120 group, n = 7) after the infusion of Et-1. As rats subjected to the 2 hours delayed hypothermic protocol had to be sedated 100 minutes longer than the H20 hypothermic protocol, we first investigated if such prolonged anaesthesia did not affect the parameters studied. Therefore, an extra group of normothermic rats was included in the study that received prolonged sedation (100 minutes extra). The results showed no differences in the determined parameters when rats were subjected to the prolonged protocol. Therefore, the results of all normothermic animals were pooled and are always referred to as the N group.
Cerebral blood flow measurement
In 12 animals the CBF was measured during the entire experimental procedure using laser Doppler flowmetry (S, N and H group; n = 4 in each group). For these experiments, an extra guide with canula was inserted into the striatum during the surgical procedure (AP +1.2, L +2.4, V +5.8, coordinates relative to bregma) . The next day when performing the experiment as described above, this guide was replaced by a laser Doppler probe (LaserFlo Blood perfusion monitor 403A, fiber optic probe P336387). This allowed continuous measurement of the CBF during the entire experimental procedure. Basal levels of the CBF were equalled to 100% .
Sensor- and motoric abnormalities were evaluated before and 24 hours after the administration of Et-1 with the use of a neurological deficit score (NDS) as previously described . Six parameters were scored between 0 to 3 or 1 to 3. Spontaneous activity, symmetry in the movement of the 4 limbs, forepaw outstretching, equality of strength in the forepaws, body proprioception and response to vibrissae touch was observed. The NDS was calculated as the sum of these scores, 18 being the best and 3 the worst possible score [37, 40]. To ascertain unbiased results, behavioural testing was performed by observers, blinded to the treatment protocol.
Infarct volume determination
Exactly 24 hours after the infusion of Et-1, after the behavioural analysis, rats were deeply anaesthetized with 6% pentobarbital. The brains were fixated by a transcardial perfusion with 5 minutes of saline and 5 minutes of a freshly prepared 4% phosphate buffered paraformaldehyde solution and then stored in the same buffer. Coronal sections of 50 μm were cut and stored in phosphate buffered saline (PBS, 0.01 M) containing sodium azide (0.1%) as a preservative. The infarct area was visualized every 200 μm by a Nissl staining. At a magnification of 1.25, microscope pictures of the stained slices were taken and transferred to the computer program Image J (NIH, version 1.37) to calculate the infarct volume stereologically. After scaling, the marked infarcted area and hemisphere (in mm2) could be calculated and was multiplied with the interspace. The influence of oedema on the infarct volume was corrected by applying the following formula: (area of normal hemisphere/area of infarcted hemisphere) x area of infarct [37, 41]. To ascertain unbiased results, determination of the infarct volume was performed by observers, blinded to the treatment protocol.
Immunohistochemistry (IHC) for active caspase-3, CD-68 and GFAP
The degree of apoptosis was determined by IHC for active caspase-3+-cells as previously described but with a slightly modified protocol . The 50 μm sections were pre-incubated with 0.01% Triton X-100, 3% hydrogen peroxide and blocking agent (Vectastain ABC kit, VectorLaboratories, Burlingame, CA, USA). Next, the sections were incubated overnight at 4°C with a 1:250 dilution of the primary monoclonal rabbit anti-caspase-3 antibody (Cell Signaling, Westburg, The Netherlands). The next day, the slices were incubated for 1 hour at room temperature with biotinylated secondary antibody (Vectastain ABC kit, VectorLaboratories, Burlingame, CA, USA) and 30 minutes with ABC reagent with blocking solution (Vectastain ABC kit, VectorLaboratories, Burlingame, CA, USA). Antibody binding was visualized using the diaminobenzidine substrate chromogen kit (DakoCytomation, Glostrup, Denmark). Between all incubations, a washing step was included. After drying, the sections were counterstained with haematoxylin/lithium carbonate.
To determine the degree of neuroinflammation, the activation status of microglia (CD-68 expression) and astrocytes (GFAP expression) was determined as previously described . After pre-incubation with 0.01% Triton X-100, 3% hydrogen peroxide and pre-immunized goat serum (1:5 dilution, Sigma, St-Louis, MO, USA), brain slices were incubated overnight at 4°C, with polyclonal mouse anti-CD-68 (1:1000 in PIG/PBS 1:5 dilution, AdB Serotec, Düsseldorf, Germany) or polyclonal rabbit anti-GFAP (1:10000 in PBS, DakoCytomation, Glostrup, Denmark). Next, the slices were incubated for 4 hours at room temperature with a 1:100 dilution of either sheep anti-mouse or monkey anti-rabbit secondary antibody (Amersham, GE Healthcare, Buckinghamshire, UK). Antibody binding was visualized using the diaminobenzidine substrate chromogen kit (DakoCytomation, Glostrup, Denmark). Between all incubations, a washing step was performed. After drying, the sections were washed with water and dehydrated by passing to graded alcohol and xylene.
For each rat, IHC protocols were performed on 3 independent slices taken from 0.2 mm anterior to 0.26 mm posterior to bregma to avoid interference of the implantation of the Et-1 probe . Alternate sections were used for the determination of the infarct volume, apoptosis or activation of glial cells. Positive caspase-3 stained cells were counted using standard light microscopy. As previous research showed that hypothermia reduces the degree of apoptosis only in the cortex after infusion of Et-1, but not in the striatum, counting of active caspase-3+-cells was limited to the cortex [20, 21]. The total number of caspase-3 positive cells was counted in the entire cortex of the ischemic hemisphere. CD-68 positive cells were counted in striatum and cortex [22, 37]. For GFAP expression, the high density of cells did not allow counting. Therefore, the relative staining intensity was calculated in each rat: mean gray value ipsilateral striatum (or cortex) – mean gray value contralateral striatum (or cortex), using Image J (NIH, version 1.37). Besides, calculating the difference in intensity between the ipsi- and the contralateral side is advantageous to correct for variations in circumstances when the IHC protocols were performed. To ascertain unbiased results, counting was performed by observers, blinded to the treatment protocol.
Correlation between the number of apoptotic cells, the infarct volume and the NDS
The correlation between the number of apoptotic cells, the infarct volume and the NDS was investigated. Each point represents the mean of the S, N, H20, H60 and H120 group. The calculated r2 values represent the coefficient of determination (square of the Pearson correlation coefficient) and are a measure for the extent to which a variance in the two variables is shared.
All data are expressed as mean ± SEM and a p-value < 0.05 was considered significant. Data analysis was performed using the statistical program Graphpad InStat (version 3.06 Windows XP, GraphPad Software, San Diego, California, USA). To compare the results between the different groups, a one-way ANOVA with Bonferroni post-hoc test was used. For the changes of the CBF as a function of time in each group, a repeated measures ANOVA was used with Dunnett post-hoc test compared to the CBF before the injection of Et-1.
Mild hypothermia has no effect on the CBF
Sham animals showed no change in CBF during or after administration of the vehicle. In normothermic conditions, administration of 500 pmol Et-1 (at t = 0 minutes) resulted in an immediate significant reduction in CBF for 20 minutes to approximately 20% of the baseline values. Forty minutes after the insult, a slight hyperperfusion phase could be distinguished during which the CBF increased to about 110% of baseline values. Gradually, however, the CBF decreased back to approximately 75% of basal values. The hypothermic treatment, started 20 minutes after the Et-1 administration, had no effect on the changes in blood flow observed in normothermic conditions. So, induction of hypothermia in our model does not affect the CBF (Figure 2).
Delaying hypothermia up to 1 hour after the administration of Et-1 is still neuroprotective and improves functional and neurological outcome
The minor surgery required to implant the probe by which Et-1 was administered, had no effect on the NDS (data not shown). Comparison of the NDS before infusion (control) of vehicle in the sham rats and 24 hours afterwards showed no significant difference. The NDS of the S + H group was not different from the control group. Et-1 administration in normothermic conditions significantly reduced the NDS compared to the sham rats. The NDS in the H20, 60 or 120 group was also lower than in the S group. The hypothermic treatment initiated either 20 or 60 minutes after the ischemic insult significantly improved the neurological deficit compared to the normothermic group, whereas the treatment initiated after 120 minutes was ineffective (Figure 3).
Sham operated animals (S and the S + H group) showed no infarct, while in the normothermic rats a large area of damaged tissue stretching from the striatum (the core of the insult) into the surrounding cortex (the penumbra) was present. Hypothermia, initiated 20 minutes after the insult reduced the infarct volume by almost half. Salvation of tissue by hypothermia predominantly took place in the penumbral region, in accordance with previous findings from our laboratory [21, 37]. Hypothermia, initiated 60 minutes after the ischemic insult, also significantly reduced the infarct volume. However, when the hypothermic treatment was delayed up to 2 hours after the insult, the infarct volume did not show any significant improvement compared to normothermic rats anymore (Figure 4).
Hypothermia reduces the amount of active caspase-3+-cells by half, even if only initiated 1 hour after the administration of Et-1
No positive staining was observed in sham rats (S and S + H group) and in the hemisphere contralateral to the site of Et-1 infusion. Administration of Et-1, on the other hand, resulted in a massive increase in apoptotic cell death (Figure 5). The hypothermic treatment initiated 20 or 60 minutes after the insult resulted in a 50 or 45% reduction in apoptotic cells respectively. However, starting hypothermia as late as 2 hours after the Et-1 administration did not reduce the amount of apoptotic cells significantly, compared to normothermic rats.
The number of apoptotic cells correlates well with the infarct volume and the NDS
The number of apoptotic cells correlated well with infarct volume (r2 = 0.96) and even better with the NDS (r2 = 0.99) (Figure 6). The NDS also correlated well with the infarct volume (r2 = 0.96) (data not shown).
Delaying hypothermia up to 2 hours after stroke onset, still reduces CD-68 expression but not GFAP expression
Cerebral ischemia induces neuroinflammation which is initiated by activation of microglia and their transformation into resident macrophages and subsequent infiltration of leukocytes, including neutrophils and macrophages. Blood-borne and resident macrophages/activated microglia can be visualized by anti-CD-68 staining. No positive staining was observed in the hemisphere contralateral to the site of Et-1 infusion. Sham operated rats showed a low number of CD-68+-cells in the striatum, in contrast to the cortex, where a significant amount of CD-68+-cells was observed. Cooling down sham rats reduced the expression of CD-68 in the cortex. Administration of Et-1 resulted in an increased CD-68 expression in striatum and cortex, in accordance with previous findings . The hypothermic treatment, even if delayed up to 2 hours after the infusion of Et-1 significantly reduced the amount of phagocytic cells in the striatum. However, in the cortex, although a strong reduction in CD-68+-cells was visible after all treatment protocols, this effect was only statistically significant for the H20 group (Figure 7).
Activated astrocytes were visualized by IHC for GFAP. Low expression of GFAP was present in the striatum and the cortex of the sham rats (S and S + H group). Consistent with our previous findings, a massive increase in GFAP expression occurred in the striatum and cortex of the normothermic animals. Hypothermic treatment after Et-1 significantly reduced the GFAP expression even when hypothermia was delayed for 2 hours after the insult. The strongest reduction in GFAP expression was observed in the striatum of the H20 group. The levels of the H60 group were higher than the H20 group, but stayed significantly lower than the untreated N group. The same was seen in the H120 group but the levels decreased again slightly compared to the H60 group, although not significantly different from each other. Reduction in GFAP expression was also observed in the cortex but was less pronounced than in the striatum (Figure 8).
It is generally accepted that reducing the body temperature to 33-34°C is neuroprotective against cerebral ischemic insults without causing many side effects [9, 28, 29]. Here, we show that, in the Et-1 model, a short mild hypothermic treatment can be delayed up to 1 hour after stroke onset without losing its beneficial effect. Although the reduction in neurological and functional deficit and apoptosis was no longer observed after delaying hypothermia for 2 hours, this study clearly shows a lasting inhibitory effect on activation of glia. Laser-doppler flowmetry experiments in the striatum showed no influence of cooling on the MCA occlusion caused by Et-1. Finally, we show a clear correlation between neurological and functional outcome with apoptosis but not with inflammation.
The STAIR criteria suggest to reproduce data in as many experimental stroke models as possible, especially in models mimicking hospital settings. In the Et-1 model, as reperfusion is only established slowly, it resembles clinical reality closely and thus data could be extrapolated to the clinic . Besides, due to the short half-life of Et-1 (1.4 to 3.6 minutes) , infusion of this vasoconstrictor leads to an occlusion (>75%) of the MCA for 20–30 minutes, before a gradual reperfusion . Afterwards the blood flow is restored. As such, a reproducible infarct with a clear distinction between the core (striatum) and the penumbra (cortex) of the insult is established and it becomes possible to distinguish certain effects solely to the core or penumbral area [21, 37]. Our study showed that cooling had no influence on the MCAO caused by Et-1. This result indicates that the effects of hypothermia are not mediated by modulation of the CBF.
Since cells in the penumbra undergoing apoptosis are major targets for intervention , we assessed the number of cells containing active caspase-3. Previously, we demonstrated that apoptosis in the penumbra occurs in the subacute phase and peaks 24 hours after the insult . Chaitanya et al.  showed that 3 hours MCAO induces apoptosis, reaching maximal levels at 24 and 72 hours after the insult . Another study investigated the effect of 20 minutes and 2 hours MCAO on apoptosis. They observed that caspase-3 activity peaks at 24 and 72 hours after reperfusion in the 20 minutes MCAO group, whereas, it only peaks at 24 hours after 2 hours MCAO . These results are consistent with our data. Previous research in our laboratory also investigated nuclear fragmentation in neuronal cells and showed 24 hours after the insult that mild hypothermia significantly affected apoptotic neuronal cell death in the penumbral region, consistent with the effects observed here on activated caspase-3 expression . Phanithi et al.  showed that intra-ischemic mild hypothermia inhibits the caspase-3 expression in the penumbra, at 24 hours, after 1 hour of focal ischemia . Maier et al.  confirmed that 1 and 2 hours of intra-ischemic mild hypothermia was effective to reduce apoptosis at 72 hours after the insult . Similar results on infarct volume have been reported. For instance, Maier et al.  showed, 3 days after the insult, that 2 hours of hypothermia reduced the infarct volume, even when delayed up to 90 minutes after 2 hours MCAO . In the same MCAO model, 4 hours of post-ischemic hypothermia (started 4 hours after ischemia onset), could no longer protect the rat brain [48, 49]. However, a study by Ohta  showed that the hypothermic treatment could be delayed up to 4 hours after 2 hours MCAO if cooling was prolonged for 48 hours . However, serious side effects are then to be expected, but were not investigated.
In our study, the number of apoptotic cells correlates well with infarct volume (r2 = 0.96) and with neurological deficit (r2 = 0.99). This observation is in accordance with the general idea that cell death in the penumbra, which is the predominant area that is salvaged by hypothermia, occurs through apoptosis [19–21, 44]. It is also coherent with our hypothesis that the beneficial effects of short hypothermic treatment on infarct volume and neurological deficit are predominantly mediated by inhibition of apoptosis in the penumbra, at least as established at 24 hours after the insult.
After infusion of Et-1, CD-68 expression increased in the striatum and the cortex of the insult after 24 hours. These results are consistent with previous findings in the Et-1 model  and other MCAO models [51–53]. The hypothermic treatment significantly attenuated this increase by approximately 50%, when initiated 20 minutes after the infusion of Et-1. Similar results were obtained in studies investigating the effect of 2 hours of intra-ischemic mild hypothermic treatment after 2 hours MCAO. They showed a reduction of the infarct volume and CD-68 expression at 1, 3 and 7 days after the insult [15, 16, 22]. Similar results were also observed after MCAO of 8 minutes . Our study further showed that delaying hypothermia for 1 or 2 hours could still reduce the amount of phagocytic cells in the core of the insult. Surprisingly, this observation did not correlate with decreased neurological or functional deficit. This could mean that a reduction in phagocytosis is not instrumental to the neuroprotective effects of hypothermia. However, it is conceivable that inhibition of microglial activation and reduced infiltration of monocytes within the first 24 hours attenuates the induction of cell death between 24 and 72 hours after the insult.
GFAP is considered the best marker to investigate reactive gliosis . Stroke induces a massive increase in GFAP expression after a day, in several stroke models ranging from 30 minutes MCAO to the photothrombosis model [56, 57]. Our study confirms these results in the Et-1 model, in the core as well as in the penumbra. Our major finding is that short hypothermic treatment reduced the expression of GFAP in the striatum and cortex. More specifically, Zoli et al.  described peak levels in astrogliosis 24 hours after the insult, especially in the penumbral area . Our results are consistent with these findings and might explain why the effect of hypothermia on GFAP expression was less pronounced compared to that in the core of the insult. Although the strongest effects were found when hypothermia was initiated after 20 minutes, delaying hypothermia up to 2 hours after the administration of Et-1 still reduces GFAP expression. Further research is necessary to clarify whether delaying short hypothermic treatment for 2 hours (or more) provides neuroprotection at later time points after the insult. However, it is also possible that increased GFAP expression after cerebral ischemia is not entirely detrimental. Indeed, GFAP null mice showed more sensitivity to ischemia compared to wild type mice [58, 59].
This study confirms that short hypothermic treatment can be protective when it is applied within a relatively short therapeutic window up to 1 h. It is known that, when the treatment is delayed, long cooling periods seem more protective [34, 35]. In a balance of risk and benefit, a short duration of hypothermia may be the initial choice. The hypothermia treatment protocol should be tailored to each patient's situation, depending on the time after the insult and whether the patient is in the intra-ischemic or in the post-ischemic period. For instance, shorter cooling periods can be induced when patients arrive very quickly in the hospital after the onset of the insult, while longer cooling periods can be applied to patients that arrive later to the hospital. Also co-morbidities should be taken into account when conducting experimental or clinical studies . Based on this assumption and the results of the available data, a larger randomized, controlled clinical trial of hypothermia in acute ischemic stroke is warranted.
Administration of Et-1 resulted in an ischemic stroke associated with neurological deficit and a large infarct volume, 24 hours after the insult. Furthermore, apoptosis and gliosis were stimulated. Two hours of a short mild hypothermic treatment, initiated after 20 or 60 minutes improved neurological deficit and infarct volume, and coincided with a reduction in apoptotic cells. Glial activation, on the contrary, remained inhibited even when hypothermia was only induced after 2 hours. These data indicate that in the Et-1 rat model, a short mild hypothermic treatment delayed for 1 hour is still neuroprotective and correlates with apoptosis. At the same time, hypothermia also establishes a lasting inhibitory effect on the activation of astrogliosis.
Candelario-Jalil E: Injury and repair mechanisms in ischemic stroke: considerations for the development of novel neurotherapeutics. Curr Opin Investig Drugs. 2009, 10 (7): 644-654.
Lyden PD, Krieger D, Yenari M, Dietrich WD: Therapeutic hypothermia for acute stroke. Int J Stroke. 2006, 1 (1): 9-19. 10.1111/j.1747-4949.2005.00011.x.
Zhao H, Steinberg GK, Sapolsky RM: General versus specific actions of mild-moderate hypothermia in attenuating cerebral ischemic damage. J Cereb Blood Flow Metab. 2007, 27 (12): 1879-1894. 10.1038/sj.jcbfm.9600540.
Hachimi-Idrissi S, Corne L, Ebinger G, Michotte Y, Huyghens L: Mild hypothermia induced by a helmet device: a clinical feasibility study. Resuscitation. 2001, 51 (3): 275-281. 10.1016/S0300-9572(01)00412-9.
Liu L, Yenari MA: Therapeutic hypothermia: neuroprotective mechanisms. Front Biosci. 2007, 12: 816-825. 10.2741/2104.
De Georgia MA, Krieger DW, Abou-Chebl A, Devlin TG, Jauss M, Davis SM, Koroshetz WJ, Rordorf G, Warach S: Cooling for Acute Ischemic Brain Damage (COOL AID): a feasibility trial of endovascular cooling. Neurology. 2004, 63 (2): 312-317. 10.1212/01.WNL.0000129840.66938.75.
Hemmen TM, Raman R, Guluma KZ, Meyer BC, Gomes JA, Cruz-Flores S, Wijman CA, Rapp KS, Grotta JC, Lyden PD: Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuS-L): final results. Stroke. 2010, 41 (10): 2265-2270. 10.1161/STROKEAHA.110.592295.
Colbourne F, Corbett D, Zhao Z, Yang J, Buchan AM: Prolonged but delayed postischemic hypothermia: a long-term outcome study in the rat middle cerebral artery occlusion model. J Cereb Blood Flow Metab. 2000, 20 (12): 1702-1708.
Maier CM, Ahern K, Cheng ML, Lee JE, Yenari MA, Steinberg GK: Optimal depth and duration of mild hypothermia in a focal model of transient cerebral ischemia: effects on neurologic outcome, infarct size, apoptosis, and inflammation. Stroke. 1998, 29 (10): 2171-2180. 10.1161/01.STR.29.10.2171.
Hammer MD, Krieger DW: Acute ischemic stroke: is there a role for hypothermia?. Cleve Clin J Med. 2002, 69 (10): 770-10.3949/ccjm.69.10.770. 773–774, 776–777 passim
Marion D, Bullock MR: Current and future role of therapeutic hypothermia. J Neurotrauma. 2009, 26 (3): 455-467. 10.1089/neu.2008.0582.
Schwab S, Georgiadis D, Berrouschot J, Schellinger PD, Graffagnino C, Mayer SA: Feasibility and safety of moderate hypothermia after massive hemispheric infarction. Stroke. 2001, 32 (9): 2033-2035. 10.1161/hs0901.095394.
Zgavc T, Ceulemans AG, Sarre S, Michotte Y, Hachimi-Idrissi S: Experimental and clinical use of therapeutic hypothermia for ischemic stroke: opportunities and limitations. Stroke Res Treat. 2011, 2011: 689290.
Bell TE, Kongable GL, Steinberg GK: Mild hypothermia: an alternative to deep hypothermia for achieving neuroprotection. J Cardiovasc Nurs. 1998, 13 (1): 34-44.
Deng H, Han HS, Cheng D, Sun GH, Yenari MA: Mild hypothermia inhibits inflammation after experimental stroke and brain inflammation. Stroke. 2003, 34 (10): 2495-2501. 10.1161/01.STR.0000091269.67384.E7.
Han HS, Qiao Y, Karabiyikoglu M, Giffard RG, Yenari MA: Influence of mild hypothermia on inducible nitric oxide synthase expression and reactive nitrogen production in experimental stroke and inflammation. J Neurosci. 2002, 22 (10): 3921-3928.
Kelly S, Cheng D, Steinberg GK, Yenari MA: Mild hypothermia decreases GSK3beta expression following global cerebral ischemia. Neurocrit Care. 2005, 2 (2): 212-217. 10.1385/NCC:2:2:212.
Maier CM, Sun GH, Cheng D, Yenari MA, Chan PH, Steinberg GK: Effects of mild hypothermia on superoxide anion production, superoxide dismutase expression, and activity following transient focal cerebral ischemia. Neurobiol Dis. 2002, 11 (1): 28-42. 10.1006/nbdi.2002.0513.
Maier CM, Sun GH, Kunis D, Yenari MA, Steinberg GK: Delayed induction and long-term effects of mild hypothermia in a focal model of transient cerebral ischemia: neurological outcome and infarct size. J Neurosurg. 2001, 94 (1): 90-96. 10.3171/jns.2001.94.1.0090.
Van Hemelrijck A, Hachimi-Idrissi S, Sarre S, Ebinger G, Michotte Y: Post-ischaemic mild hypothermia inhibits apoptosis in the penumbral region by reducing neuronal nitric oxide synthase activity and thereby preventing endothelin-1-induced hydroxyl radical formation. Eur J Neurosci. 2005, 22 (6): 1327-1337. 10.1111/j.1460-9568.2005.04331.x.
Van Hemelrijck A, Vermijlen D, Hachimi-Idrissi S, Sarre S, Ebinger G, Michotte Y: Effect of resuscitative mild hypothermia on glutamate and dopamine release, apoptosis and ischaemic brain damage in the endothelin-1 rat model for focal cerebral ischaemia. J Neurochem. 2003, 87 (1): 66-75. 10.1046/j.1471-4159.2003.01977.x.
Wang GJ, Deng HY, Maier CM, Sun GH, Yenari MA: Mild hypothermia reduces ICAM-1 expression, neutrophil infiltration and microglia/monocyte accumulation following experimental stroke. Neuroscience. 2002, 114 (4): 1081-1090. 10.1016/S0306-4522(02)00350-0.
Yenari MA, Zhao H, Giffard RG, Sobel RA, Sapolsky RM, Steinberg GK: Gene therapy and hypothermia for stroke treatment. Ann N Y Acad Sci. 2003, 993: 54-68. 10.1111/j.1749-6632.2003.tb07511.x. discussion 79–81
Zhang Z, Sobel RA, Cheng D, Steinberg GK, Yenari MA: Mild hypothermia increases Bcl-2 protein expression following global cerebral ischemia. Brain Res Mol Brain Res. 2001, 95 (1–2): 75-85.
Zhao H, Wang JQ, Shimohata T, Sun G, Yenari MA, Sapolsky RM, Steinberg GK: Conditions of protection by hypothermia and effects on apoptotic pathways in a rat model of permanent middle cerebral artery occlusion. J Neurosurg. 2007, 107 (3): 636-641. 10.3171/JNS-07/09/0636.
Zhao H, Yenari MA, Sapolsky RM, Steinberg GK: Mild postischemic hypothermia prolongs the time window for gene therapy by inhibiting cytochrome C release. Stroke. 2004, 35 (2): 572-577. 10.1161/01.STR.0000110787.42083.58.
Dietrich WD, Atkins CM, Bramlett HM: Protection in animal models of brain and spinal cord injury with mild to moderate hypothermia. J Neurotrauma. 2009, 26 (3): 301-312. 10.1089/neu.2008.0806.
Kollmar R, Schwab S: Hypothermia in focal ischemia: implications of experiments and experience. J Neurotrauma. 2009, 26 (3): 377-386. 10.1089/neu.2008.0564.
Tang XN, Liu L, Yenari MA: Combination therapy with hypothermia for treatment of cerebral ischemia. J Neurotrauma. 2009, 26 (3): 325-331. 10.1089/neu.2008.0594.
Callaway JK, Knight MJ, Watkins DJ, Beart PM, Jarrott B: Delayed treatment with AM-36, a novel neuroprotective agent, reduces neuronal damage after endothelin-1-induced middle cerebral artery occlusion in conscious rats. Stroke. 1999, 30 (12): 2704-2712. 10.1161/01.STR.30.12.2704. discussion 2712
Macrae IM, Robinson MJ, Graham DI, Reid JL, McCulloch J: Endothelin-1-induced reductions in cerebral blood flow: dose dependency, time course, and neuropathological consequences. J Cereb Blood Flow Metab. 1993, 13 (2): 276-284. 10.1038/jcbfm.1993.34.
Sicard KM, Fisher M: Animal models of focal brain ischemia. Exp Transl Stroke Med. 2009, 1: 7-10.1186/2040-7378-1-7.
Windle V, Szymanska A, Granter-Button S, White C, Buist R, Peeling J, Corbett D: An analysis of four different methods of producing focal cerebral ischemia with endothelin-1 in the rat. Exp Neurol. 2006, 201 (2): 324-334. 10.1016/j.expneurol.2006.04.012.
Clark DL, Penner M, Orellana-Jordan IM, Colbourne F: Comparison of 12, 24 and 48 h of systemic hypothermia on outcome after permanent focal ischemia in rat. Exp Neurol. 2008, 212 (2): 386-392. 10.1016/j.expneurol.2008.04.016.
Yanamoto H, Nagata I, Nakahara I, Tohnai N, Zhang Z, Kikuchi H: Combination of intraischemic and postischemic hypothermia provides potent and persistent neuroprotection against temporary focal ischemia in rats. Stroke. 1999, 30 (12): 2720-2726. 10.1161/01.STR.30.12.2720. discussion 2726
Schaller B, Graf R: Hypothermia and stroke: the pathophysiological background. Pathophysiology. 2003, 10 (1): 7-35. 10.1016/j.pathophys.2003.09.001.
Ceulemans AG, Zgavc T, Kooijman R, Hachimi-Idrissi S, Sarre S, Michotte Y: Mild hypothermia causes differential, time-dependent changes in cytokine expression and gliosis following endothelin-1-induced transient focal cerebral ischemia. J Neuroinflammation. 2011, 8: 60-10.1186/1742-2094-8-60.
Paxinos G, Watson G: The Rat Brain in Stereotaxic Coordinates. 1986, New York: Academic
Bogaert L, Scheller D, Moonen J, Sarre S, Smolders I, Ebinger G, Michotte Y: Neurochemical changes and laser Doppler flowmetry in the endothelin-1 rat model for focal cerebral ischemia. Brain Res. 2000, 887 (2): 266-275. 10.1016/S0006-8993(00)02959-0.
Garcia JH, Wagner S, Liu KF, Hu XJ: Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation. Stroke. 1995, 26 (4): 627-634. 10.1161/01.STR.26.4.627. discussion 635
Weston RM, Jones NM, Jarrott B, Callaway JK: Inflammatory cell infiltration after endothelin-1-induced cerebral ischemia: histochemical and myeloperoxidase correlation with temporal changes in brain injury. J Cereb Blood Flow Metab. 2007, 27 (1): 100-114. 10.1038/sj.jcbfm.9600324.
Durukan A, Tatlisumak T: Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol Biochem Behav. 2007, 87 (1): 179-197. 10.1016/j.pbb.2007.04.015.
Parker JD, Thiessen JJ, Reilly R, Tong JH, Stewart DJ, Pandey AS: Human endothelin-1 clearance kinetics revealed by a radiotracer technique. J Pharmacol Exp Ther. 1999, 289 (1): 261-265.
Broughton BR, Reutens DC, Sobey CG: Apoptotic mechanisms after cerebral ischemia. Stroke. 2009, 40 (5): e331-e339. 10.1161/STROKEAHA.108.531632.
Chaitanya GV, Babu PP: Activation of calpain, cathepsin-b and caspase-3 during transient focal cerebral ischemia in rat model. Neurochem Res. 2008, 33 (11): 2178-2186. 10.1007/s11064-007-9567-7.
Lee SH, Kim M, Kim YJ, Kim YA, Chi JG, Roh JK, Yoon BW: Ischemic intensity influences the distribution of delayed infarction and apoptotic cell death following transient focal cerebral ischemia in rats. Brain Res. 2002, 956 (1): 14-23. 10.1016/S0006-8993(02)03197-9.
Phanithi PB, Yoshida Y, Santana A, Su M, Kawamura S, Yasui N: Mild hypothermia mitigates post-ischemic neuronal death following focal cerebral ischemia in rat brain: immunohistochemical study of Fas, caspase-3 and TUNEL. Neuropathology. 2000, 20 (4): 273-282. 10.1046/j.1440-1789.2000.00346.x.
Kawai N, Okauchi M, Morisaki K, Nagao S: Effects of delayed intraischemic and postischemic hypothermia on a focal model of transient cerebral ischemia in rats. Stroke. 2000, 31 (8): 1982-1989. 10.1161/01.STR.31.8.1982. discussion 1989
Kawamura N, Schmeichel AM, Wang Y, Schmelzer JD, Low PA: Multiple effects of hypothermia on inflammatory response following ischemia-reperfusion injury in experimental ischemic neuropathy. Exp Neurol. 2006, 202 (2): 487-496. 10.1016/j.expneurol.2006.07.012.
Ohta H, Terao Y, Shintani Y, Kiyota Y: Therapeutic time window of post-ischemic mild hypothermia and the gene expression associated with the neuroprotection in rat focal cerebral ischemia. Neurosci Res. 2007, 57 (3): 424-433. 10.1016/j.neures.2006.12.002.
Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM: Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther. 2007, 321 (3): 892-901. 10.1124/jpet.107.120188.
Yenari MA, Han HS: Influence of hypothermia on post-ischemic inflammation: role of nuclear factor kappa B (NFkappaB). Neurochem Int. 2006, 49 (2): 164-169. 10.1016/j.neuint.2006.03.016.
Zhang Z, Chopp M, Powers C: Temporal profile of microglial response following transient (2 h) middle cerebral artery occlusion. Brain Res. 1997, 744 (2): 189-198. 10.1016/S0006-8993(96)01085-2.
Webster CM, Kelly S, Koike MA, Chock VY, Giffard RG, Yenari MA: Inflammation and NFkappaB activation is decreased by hypothermia following global cerebral ischemia. Neurobiol Dis. 2009, 33 (2): 301-312. 10.1016/j.nbd.2008.11.001.
Pekny M, Nilsson M: Astrocyte activation and reactive gliosis. Glia. 2005, 50 (4): 427-434. 10.1002/glia.20207.
Nowicka D, Rogozinska K, Aleksy M, Witte OW, Skangiel-Kramska J: Spatiotemporal dynamics of astroglial and microglial responses after photothrombotic stroke in the rat brain. Acta Neurobiol Exp (Wars). 2008, 68 (2): 155-168.
Zoli M, Grimaldi R, Ferrari R, Zini I, Agnati LF: Short- and long-term changes in striatal neurons and astroglia after transient forebrain ischemia in rats. Stroke. 1997, 28 (5): 1049-1058. 10.1161/01.STR.28.5.1049. discussion 1059
Cordeau P, Lalancette-Hebert M, Weng YC, Kriz J: Live imaging of neuroinflammation reveals sex and estrogen effects on astrocyte response to ischemic injury. Stroke. 2008, 39 (3): 935-942. 10.1161/STROKEAHA.107.501460.
Nawashiro H, Brenner M, Fukui S, Shima K, Hallenbeck JM: High susceptibility to cerebral ischemia in GFAP-null mice. J Cereb Blood Flow Metab. 2000, 20 (7): 1040-1044.
We would like to thank Mr. G. De Smet, Mrs. C. De Rijck, Mrs. R. Berckmans, Mrs. R-M Geens and Mrs. G. De Boeck for their technical assistance and Ms. K. De Veirman for practical help. This work was supported by the Research Fund from the Vrije Universiteit Brussel (OZR-VUB), by the Instituut voor de Aanmoediging van Innovatie door Wetenschap en Technologie in Vlaanderen (IWT-TBM) and the Fonds voor Wetenschappelijk Onderzoek (FWO-Vlaanderen) (G.0215.08 and G019112N). An-Gaëlle Ceulemans is a research fellow of the FWO-Vlaanderen.
The authors declare no conflict of interest.
TZ, A-GC, SS, YM, RK and SH participated in the design of the study. TZ, A-GC carried out the data acquisition. In particular, A-GC participated. SS, RK, SH and YM provided writing assistance. In particular, SS participated in the statistical analysis. All authors read and approved the final manuscript.
Tine Zgavc, An-Gaëlle Ceulemans contributed equally to this work.